Goldfinch brings together experts in the field and experienced leaders with a shared mission to pioneer new treatments for patients with kidney disease.


Anthony Johnson, M.D.

Chief Executive Officer

Michael Broxson

Chief Business and Operating Officer

Frank S. Czerwiec, M.D., Ph.D.

Chief Medical Officer

Peter Mundel, M.D.

Chief Scientific Officer

Jean-Christophe Harmange, Ph.D.

Senior Vice President of Drug Discovery

Lori Rudolph-Owen, Ph.D.

Senior Vice President, R&D Strategy and Operations

Thomas Tibbitts, Ph.D.

Senior Vice President of Computational Discovery

Curtis Demick

Vice President of Human Resources

John F. Reilly, Ph.D.

Vice President of Biology

Liron Walsh, M.D.

Vice President of Translational and Clinical Nephrology


Our Founders and Advisors are world-renowned scientists and clinicians at the forefront of kidney biology, genetics, and genomics.

Joseph Bonventre, M.D., Ph.D.

Harvard Medical School, MIT, Brigham and Women's Hospital

Anna Greka, M.D., Ph.D.

The Broad Institute, Harvard Medical School, Brigham and Women’s Hospital

Friedhelm Hildebrandt, M.D.

Harvard Medical School, Boston Children's Hospital

Daniel MacArthur, Ph.D.

The Broad Institute, Harvard Medical School, Massachusetts General Hospital

Peter Mundel, M.D.

Goldfinch Bio

Stefan Somlo, M.D.

Yale School of Medicine


Abbie Celniker, Ph.D.

Chairwoman of Goldfinch Bio and Partner, Third Rock Ventures

Louis Brenner, M.D.

President and Chief Executive Officer, Allena Pharmaceuticals

Neil Exter

Partner, Third Rock Ventures

Anthony Johnson, M.D.

Chief Executive Officer

Frank W. Maddux, M.D., F.A.C.P.

Executive Vice President and Chief Medical Officer, Fresenius Medical Care North America